Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: RECOVERY Finds Kaletra Ineffective, Indian Company Joins Vaccine Race

Plus: Could Tweaks Boost Remdesivir Benefits?

Executive Summary

A third set of authoritative results from UK trial ruled out use of AbbVie's HIV combination, plus Bharat Biotech to launch Phase I vaccine trials.

You may also be interested in...



AI Can Find Many Drugs To Repurpose For COVID-19, But Real-World Results Mixed

A study presented at a recent MIT-sponsored conference used network medicine to uncover dozens of potential opportunities for existing drugs to be repurposed for COVID-19.

Coronavirus Update: J&J Pauses COVID-19 Vaccine Trial After Unexplained Illness

J&J becomes the second company to pause a COVID-19 vaccine trial, releasing few details but emphasizing the measure's precautionary nature.

Coronavirus Update: US Adds To Antibody Push With $486m AstraZeneca Deal

After a week of monoclonal antibody therapies hitting the headlines - including a personal endorsement from President Trump - the US government bulks up its potential supplies. AZ's long-acting monoclonal antibody product enters large-scale trials for both a treatment and prophylaxis of COVID-19.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel